News & Updates
Filter by Specialty:
MRI/ultrasound fusion biopsy accurately detects PCa in men with intermediate PSA
Fusion biopsy with magnetic resonance imaging and ultrasonography (MRI/US) is an efficient method of detecting clinically significant prostate cancer (csPCa) in biopsy-naïve men with prostate specific antigen (PSA) levels 4–10 ng/mL, a new study has found.
MRI/ultrasound fusion biopsy accurately detects PCa in men with intermediate PSA
19 Nov 2021
Statins reduce hepatocellular carcinoma risk in cirrhotic patients
The risk of hepatocellular carcinoma (HCC) among patients with nonalcoholic steatohepatitis (NASH) and bridging fibrosis is low, reveals a recent study. In addition, dose-dependent statin can substantially lower the risk of HCC in patients with NASH cirrhosis.
Statins reduce hepatocellular carcinoma risk in cirrhotic patients
17 Nov 2021
Low carbohydrate diet lowers risk of MetS, remnant cholesterol in prostate cancer
A low carbohydrate diet (LCD) may substantially reduce the risk of metabolic syndrome (MetS) and remnant cholesterol in patients with prostate cancer, a recent study has shown.
Low carbohydrate diet lowers risk of MetS, remnant cholesterol in prostate cancer
16 Nov 2021
Drinking green tea improves gastrointestinal function recovery after gastrectomy
Patients with gastric cancer who drink green tea following robotic or laparoscopic subtotal gastrectomy show enhanced postoperative recovery of gastrointestinal function, reveals a study.
Drinking green tea improves gastrointestinal function recovery after gastrectomy
15 Nov 2021
Risk of colorectal cancer death following adenoma removal greater in women vs men
There appears to be a sex-specific difference in the risk of colorectal cancer death after adenoma removal, with women being at higher risk than men, according to a study.
Risk of colorectal cancer death following adenoma removal greater in women vs men
15 Nov 2021
Chemoimmunotherapeutic agents boost lymphocytic leukaemia survival
The introduction and use of chemoimmunotherapeutic agents such as rituximab, ofatumumab, and obinutuzumab has led to population-level improvements in survival from chronic lymphocytic leukaemia (CLL), a recent study has found.